MPLT MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. (MPLT) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 15% planned / 85% discretionary
Largest single sale: $595.4K.
Where they traded
Last open-market purchase: August 14, 2026 , by Catalyst4, Inc. .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Kroeger Christopher A. | Chief Executive Officer | Sell | 73,691 | $8.08 | $595.4K | 1,195,909 −5.8% of holding | |
| Foff Erin Pennock | Chief Medical Officer | Sell | 15,355 | $8.08 | $124.1K | 296,906 −4.9% of holding | |
| Kreitzer Anatol | Chief Discovery Officer | Sell | 12,248 | $7.84 | $96.0K | 168,678 −6.8% of holding | |
| Lillie James Woodruff | Chief Scientific Officer | Sell | 11,513 | $8.08 | $93.0K | 198,597 −5.5% of holding | |
| GILLIS JONATHAN | CAO and Interim CFO | Sell | 10,167 | $8.08 | $82.1K | 142,315 −6.7% of holding | |
| Hanson Kristopher | General Counsel | Sell | 9,020 | $8.08 | $72.9K | 128,024 −6.6% of holding | |
| Hanson Kristopher | General Counsel | Sell 10b5-1 | 16,509 | $11.67 | $192.7K | 137,044 −10.8% of holding | |
| Catalyst4, Inc. | 10% Owner | Buy | 4,400,000 | $11.38 | $50.1M | 25,306,689 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.